Additionally, research is underway to assess a combination therapy involving domvanalimab, a humanized IgG1 mAb for TIGIT, alongside zimberelimab (aPD-1) [NCT04736173, and NCT05502237] for PD-L1-high NSCLC and with durvalumab [NCT05211895] for lung cancer. This evidence concerns the gene CD274 and non-small cell lung carcinoma.